CD19 and acute lymphoblastic leukemia: In patients with B-ALL, CD19 F-CAR-T cells exhibited greater toxicity, tripling the incidence of CRS (96% overall; 24% grade ≥3) and doubling ICANS (28%, all grade ≥3).